SCHEMBL5876186

SCHEMBL5876186

Cc1ccc(S(=O)(=O)n2nc(C(=O)O)c3c2CC(c2ccccc2)(c2ccccc2)C=C3)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.42
NR1H2 P55055 1/20 0.41
NR1H3 Q13133 1/20 0.41
NPSR1 Q6W5P4 1/20 0.36
GAA P10253 1/20 0.36
SLC9A1 P19634 1/20 0.36
ALDH1A1 P00352 3/20 0.35
LMNA P02545 1/20 0.35
TSHR P16473 1/20 0.35
ALOX12 P18054 1/20 0.35
HDAC3 O15379 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
HPGD P15428 2/20 0.35
HTT P42858 1/20 0.35
HSD17B10 Q99714 1/20 0.35
KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5876231 0.96 CYP2C19 (0.39) CYP2C19NR1H2NR1H3NPSR1GAA
SCHEMBL5877142 0.94 CYP2C19 (0.38) CYP2C19NR1H2NR1H3GAAALDH1A1
SCHEMBL5876034 0.93 NR1H2 (0.36) CYP2C19NR1H2NR1H3GAAALDH1A1
SCHEMBL5876634 0.93 ALDH1A1 (0.42) CYP2C19NR1H2NR1H3NPSR1GAA
SCHEMBL5877548 0.93 MAPT (0.42) CYP2C19NR1H2NR1H3ALDH1A1LMNA
SCHEMBL5876250 0.93 ALDH1A1 (0.37) CYP2C19NR1H2NR1H3ALDH1A1LMNA
SCHEMBL5876786 0.92 KMT2A (0.40) CYP2C19NR1H2NR1H3ALDH1A1KMT2A
SCHEMBL5877310 0.92 CYP2C19 (0.36) CYP2C19NR1H2NR1H3NPSR1GAA
SCHEMBL5877639 0.91 KMT2A (0.36) CYP2C19NR1H2NR1H3NPSR1ALDH1A1
SCHEMBL5876798 0.91 KMT2A (0.39) NR1H2NR1H3ALDH1A1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7119115-B2 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2006-10-10 US disclosed
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2004-08-19 US disclosed
EP-1414805-A1 INDAZOLE OR INDOLE DERIVATIVES, THEIR USE IN HUMAN MEDICINE AND MORE PARTICULARLY IN CANCEROLOGY Aventis Pharma S.A. (FR) 2004-05-06 EP disclosed
WO-2003011833-A1 INDAZOLE OR INDOLE DERIVATIVES, THEIR USE IN HUMAN MEDICINE AND MORE PARTICULARLY IN CANCEROLOGY AVENTIS PHARMA S.A. (FR) 2003-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology IDO1, IDO2, INMT CYP2C19 13/4885NR1H2 556/4885NR1H3 456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.